

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
Mylan Inc.	05/14/2010
Dey Pharma, L.P.	05/14/2010
Dey, Inc.	05/14/2010
Mylan Technologies, Inc.	05/14/2010
Mylan Pharmaceuticals Inc.	05/14/2010

RECEIVING PARTY DATA

Name:	JPMorgan Chase Bank, N.A., as Administrative Agent
Street Address:	10 South Dearborn
City:	Chicago
State/Country:	ILLINOIS
Postal Code:	60603

PROPERTY NUMBERS Total: 27

Property Type	Number
Application Number:	11250256
Application Number:	11250220
Application Number:	11931380
Application Number:	11931424
Application Number:	11931484
Application Number:	11250925
Application Number:	11316458
Application Number:	11541523
Application Number:	12340355
Application Number:	12625328
Application Number:	12692095
Application Number:	12704767

CH \$1080.00 11250256

501203928

PATENT
REEL: 024532 FRAME: 0227

Application Number:	12173125
Application Number:	12366931
Application Number:	12366866
Application Number:	11594224
Application Number:	12286236
Application Number:	12057728
Application Number:	12272706
Application Number:	11899136
Application Number:	12589380
Application Number:	12475390
Application Number:	12454782
Application Number:	12372333
Application Number:	12372359
Application Number:	12406272
Application Number:	12476401

CORRESPONDENCE DATA

Fax Number: (202)408-3141

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 202-408-3121 x2348

Email: jpaterso@cscinfo.com

Correspondent Name: Corporation Service Company

Address Line 1: 1090 Vermont Avenue NW, Suite 430

Address Line 4: Washington, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER:	415637-5
-------------------------	----------

NAME OF SUBMITTER:	Jean Paterson
--------------------	---------------

Total Attachments: 8

source=6-14-10 Mylan-PT#page1.tif

source=6-14-10 Mylan-PT#page2.tif

source=6-14-10 Mylan-PT#page3.tif

source=6-14-10 Mylan-PT#page4.tif

source=6-14-10 Mylan-PT#page5.tif

source=6-14-10 Mylan-PT#page6.tif

source=6-14-10 Mylan-PT#page7.tif

source=6-14-10 Mylan-PT#page8.tif

Patent Security Agreement

PATENT SECURITY AGREEMENT, dated as of May 14, 2010 among MYLAN INC. (formerly Mylan Laboratories Inc.), DEY PHARMA, L.P. (formerly Dey, L.P.), DEY, INC., MYLAN TECHNOLOGIES, INC. and MYLAN PHARMACEUTICALS INC. (each individually, a "Grantor", and, collectively, the "Grantors"), in favor of JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, in its capacity as Administrative Agent (in such capacity, the "Administrative Agent") pursuant to the Amended and Restated Credit Agreement dated as December 20, 2007 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Credit Agreement") among MYLAN INC. (formerly Mylan Laboratories Inc.), MYLAN LUXEMBOURG S.A R.L., certain other parties thereto, the Lenders and the Administrative Agent.

WITNESSETH:

WHEREAS, the Grantors are party to a Guarantee and Security Agreement dated as of October 2, 2007 (as amended, amended and restated, supplemented, reaffirmed or otherwise modified from time to time, the "Security Agreement") in favor of the Administrative Agent pursuant to which the Grantors are required to execute and deliver this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent, for the benefit of the Secured Parties, to enter into and perform under the Credit Agreement, the Grantors hereby agree with the Administrative Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Security Agreement and used herein have the meaning given to them in the Security Agreement.

SECTION 2. Grant of Security Interest in Patent Collateral. Each Grantor hereby pledges and grants to the Administrative Agent for the benefit of the Secured Parties a lien on and security interest in and to all of its right, title and interest in, to and under all the following Collateral (other than Excluded Property), as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of (i) in the case of the Company, the Obligations and (ii) in the case of any Grantor other than the Company, such Grantor's Guaranteed Obligations:

- (a) Patents of such Grantor listed on Schedule I attached hereto; and
- (b) all Proceeds of any and all of the foregoing.

SECTION 3. Security Agreement. The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement and Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

SECTION 4. Termination. (i) Upon the payment in full of the Obligations (other than contingent indemnification and contingent expense reimbursement obligations, Obligations in respect of Secured Hedge Agreements and Cash Management Obligations) and termination of the Security Agreement, the Liens created hereby shall automatically be released and (ii) if any of the Collateral subject hereto shall be sold, transferred or otherwise disposed of by any Grantor (other than any sale, transfer or disposition to a Grantor) in a transaction permitted by the Credit Agreement, then the Liens created hereby on such Collateral shall automatically be released, and in each case the Administrative Agent shall execute, acknowledge, and deliver to the Grantors an instrument in writing in recordable form releasing the collateral pledge, grant, assignment, lien and security interest in the applicable Patents under this Patent Security Agreement.

SECTION 5. Counterparts. This Patent Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Patent Security Agreement by signing and delivering one or more counterparts.

[signature page follows]

IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

MYLAN INC.

By: Kristi Kolisen
Title: Senior Vice President and
Global General Counsel, Operations

DEY PHARMA, L.P.

BY: DEY, INC., its General Partner

By: Kristi Kolisen
Title: Secretary

DEY, INC.

By: Kristi Kolisen
Title: Secretary

MYLAN TECHNOLOGIES, INC.

By: Kristi Kolisen
Title: Secretary

MYLAN PHARMACEUTICALS INC.

By: Kristi Kolisen
Title: Secretary

Accepted and Agreed:

JPMORGAN CHASE BANK, NATIONAL ASSOCIATION,
as Administrative Agent

By:



Name:

Title:

Deborah R. Winkler
Vice President

Patent Security Agreement

SCHEDULE I
to
PATENT SECURITY AGREEMENT
PATENT REGISTRATIONS AND PATENT APPLICATIONS

Patent Applications:

Owner	Serial No.	Description
Dey Pharma, L.P. (formerly Dey, L.P.)	11/250,256	"Nasal Pharmaceutical Formulations And Methods Of Using The Same"
Dey Pharma, L.P. (formerly Dey, L.P.)	11/250,220	"Nasal Pharmaceutical Formulations And Methods Of Using The Same"
Dey Pharma, L.P. (formerly Dey, L.P.)	11/931,380	"Nasal Pharmaceutical Formulations And Methods Of Using The Same"
Dey Pharma, L.P. (formerly Dey, L.P.)	11/931,424	"Nasal Pharmaceutical Formulations And Methods Of Using The Same"
Dey Pharma, L.P. (formerly Dey, L.P.)	11/931,484	"Formulations And Methods Of Treating Rhi- nosinusitis"
Dey Pharma, L.P. (formerly Dey, L.P.)	11/250,925	"Formulations And Methods Of Treating Rhi- nosinusitis"
Dey Pharma, L.P. (formerly Dey, L.P.)	11/316,458	"Inhalable Formulations For Treating Pulmo- nary Hypertension And Methods Of Using The Same"
Dey Pharma, L.P. (formerly Dey, L.P.)	11/541,523	"Albuterol And Ipratropium Inhalation Solu- tion, System, Kit And Method For Relieving Symptoms of Chronic Obstructive Pulmonary Disease"
Dey Pharma, L.P. (formerly Dey, L.P.)	12/340,355	"Bronchodilating Beta-Agonist Composi- tions and Methods"
Dey Pharma, L.P. (formerly Dey, L.P.)	12/625,328	"Formoterol/Steroid Bronchodilating Composi- tions and Methods of Use Thereof"
Dey Pharma, L.P. (formerly Dey, L.P.)	12/692,095	"Formoterol/Steroid Bronchodilating Composi- tions and Methods of Use Thereof"
Dey Pharma, L.P. (formerly Dey, L.P.)	12/704,767	Nebulizable Compositions of Quaternary Am- monium Muscarinic Receptor Antagonists

Owner	Serial No.	Description
Mylan Inc.	12/173,125	Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol
Mylan Inc.	12/366,931	Compositions Comprising Nebivolol
Mylan Inc.	12/366,866	Compositions Comprising Nebivolol

Owner	Serial No.	Description
Mylan Technologies, Inc.	11/594,224	Long-Wearing Removable Pressure Sensitive Adhesive
Mylan Technologies Inc.	12/286,236	Adhesive Mixture of Transdermal Delivery of Highly Plasticizing Drugs
Mylan Technologies Inc.	12/057,728	Transdermal Systems Containing Multilayer Adhesive Matrices to modify Drug Delivery
Mylan Technologies Inc.	12/272,706	Transdermal Systems Containing Multilayer Adhesive Matrices to modify Drug Delivery
Mylan Technologies, Inc.	11/899,136	Transdermal Drug Delivery System Comprising a Coated Release Liner
Mylan Technologies Inc.	12/589,380	Adhesive Mixture for Transdermal Delivery of Highly Plasticizing Drugs
Mylan Technologies Inc.	12/475,390	Stabilized Transdermal Drug Delivery System
Mylan Technologies Inc.	12/454,782	Transdermal Systems having Control Delivery System

Owner	Serial No.	Description
Mylan Pharmaceuticals Inc.	12/372,333	Controlled Release Budesonide Minitablets
Mylan Pharmaceuticals Inc.	12/372,359	Controlled Release Budesonide Minitablets
Mylan Pharmaceuticals Inc.	12/406,272	Extended Release Formulation Containing a Wax
Mylan Pharmaceuticals Inc.	12/476,401	Fentanyl Suspension-based Silicone Adhesive Formulations and Devices for Transdermal Delivery of Fentanyl